Long Covid/PASC (general)

In this study, subjects were given a new drug called IMC-2, which is a combination of the herpesvirus antiviral drug valcyclovir and celexoxib, an anti-inflammatory which is believed to also have antiviral properties.

IMC-2 was successful in reducing long COVID symptoms, both alone and in combination with Paxlovid

A recent study published in Frontiers found that 7.7% of US healthcare workers have LongCOVID, causing high levels of burnout, depression and anxiety.

Additionally, long Covid/PASC is implicated in up to 15% of unfilled jobs, highlighting its significant impact on workforce participation.

SARS-CoV-2 drives chronic inflammation and fibrosis that stiffens musculoskeletal tissues, weakening their biomechanical integrity.

This increases injury risk post-COVID, demanding cautious, tissue-aware rehab protocols.

Long COVID myopathy is a mitochondriopathic disease, not deconditioning—driven by viral sabotage, chronic inflammation, & impaired muscle repair.

Its hallmark symptoms stem from cellular energy collapse, demanding a shift in clinical treatment paradigms.

City Doctors Blame ‘Long Covid’ For Severe Viral Infections That Have Laid Kolkata Low

A past history of ‘long or severe' Covid may have led to long-term weakening of respiratory and immune functions, making thousands in the city more vulnerable to recurrent infections, say doctors.

The gastrointestinal tract is a central driver of Long COVID pathogenesis, w/ SARS-CoV-2 infecting intestinal cells and causing inflammation, microbiome dysbiosis, and more.

Persistent viral reservoirs in the gut lead to systemic and metabolic disruption.

Organ damage might affect over 50 % of post-COVID-19 individuals and perhaps more in adolescents and children.

Review of organ damage from COVID and Long COVID: a disease with a spectrum of pathology - PMC